{"transactions":[{"id":1735103,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2023-11-20T17:07:32.000Z","date":"2023-11-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27380,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-020443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000089924323020443/doc4.xml","form_type":"4"}},{"id":1950645,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-16T16:35:31.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-019314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919123019314/doc4.xml","form_type":"4"}},{"id":2432767,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-19T16:20:32.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 14, 2023."}],"balance_after":18500,"derivative":{"exercise_price":2.21,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-003715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919122003715/doc4.xml","form_type":"4"}},{"id":2903004,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-20T16:12:16.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 15, 2022."}],"balance_after":15000,"derivative":{"exercise_price":3.85,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-004268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919121004268/doc4.xml","form_type":"4"}},{"id":3075049,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T09:01:49.000Z","date":"2020-07-24","kind":"purchase","acquired":true,"shares":21428,"price":3.5,"value":74998.0,"ownership":{"direct":true},"balance_after":27380,"source":{"system":"sec-edgar","filing":"0001209191-20-043804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919120043804/doc4.xml","form_type":"4"}},{"id":3324135,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T16:15:47.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 2, 2021."}],"balance_after":9000,"derivative":{"exercise_price":3.79,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-000887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919120000887/doc4.xml","form_type":"4"}},{"id":3675170,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-02-05T13:51:31.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on February 1, 2020."}],"balance_after":6000,"derivative":{"exercise_price":24.46,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-007240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919119007240/doc4.xml","form_type":"4"}},{"id":3696292,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Restricted Stock Units","published_at":"2019-01-15T02:48:12.000Z","date":"2019-01-11","kind":"grant","acquired":true,"shares":724848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement)."}],"balance_after":724848,"derivative":{"underlying":"Common Stock","underlying_shares":724848},"source":{"system":"sec-edgar","filing":"0001280776-19-000015","document":"wf-form4_154752047327275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/wf-form4_154752047327275.xml","form_type":"4"}},{"id":3696291,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:48:12.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001280776-19-000015","document":"wf-form4_154752047327275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/wf-form4_154752047327275.xml","form_type":"4"}},{"id":3696290,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:48:12.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001280776-19-000015","document":"wf-form4_154752047327275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/wf-form4_154752047327275.xml","form_type":"4"}},{"id":3696289,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:48:12.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":8.28,"expiration_date":"2026-05-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001280776-19-000015","document":"wf-form4_154752047327275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/wf-form4_154752047327275.xml","form_type":"4"}},{"id":3696288,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-15T02:48:12.000Z","date":"2019-01-11","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of November 17, 2014, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":19.03,"expiration_date":"2024-11-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001280776-19-000015","document":"wf-form4_154752047327275.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/wf-form4_154752047327275.xml","form_type":"4"}},{"id":3898227,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T23:22:15.000Z","date":"2018-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":45000,"derivative":{"exercise_price":5,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001280776-18-000068","document":"wf-form4_152875931831922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077618000068/wf-form4_152875931831922.xml","form_type":"4"}},{"id":4190356,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2017-10-06T16:10:58.000Z","date":"2017-10-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on October 4, 2018."}],"balance_after":6000,"derivative":{"exercise_price":15.34,"expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001654954-17-009222","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000165495417009222/section16.xml","form_type":"4"}},{"id":4204211,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true}}],"security":"Nonqualified Stock Option (right to buy)","published_at":"2017-09-21T17:25:42.000Z","date":"2017-09-19","kind":"other","acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Received in connection with the Merger in exchange for an option to acquire 16,000 shares of common stock of Private Acer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in connection with the Merger in exchange for an option to acquire 16,000 shares of common stock of Private Acer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in eight equal quarterly installments beginning on October 19, 2015."}],"balance_after":16000,"derivative":{"exercise_price":2.55,"expiration_date":"2025-10-19","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001654954-17-008688","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000165495417008688/section16.xml","form_type":"4"}},{"id":4204210,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-09-21T17:25:42.000Z","date":"2017-09-19","kind":"other","acquired":true,"shares":5952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in connection with the Issuer's business combination (the \"Merger\") with what was then known as \"Acer Therapeutics Inc.\" (\"Private Acer\") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 5,952 shares of common stock of Private Acer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination (the \"Merger\") with what was then known as \"Acer Therapeutics Inc.\" (\"Private Acer\") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 5,952 shares of common stock of Private Acer."}],"balance_after":5952,"source":{"system":"sec-edgar","filing":"0001654954-17-008688","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000165495417008688/section16.xml","form_type":"4"}},{"id":4280511,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2017-06-15T20:29:52.000Z","date":"2017-06-14","kind":"purchase","acquired":true,"shares":2400,"price":3.0904,"value":7416.96,"ownership":{"direct":true},"balance_after":11885,"source":{"system":"sec-edgar","filing":"0001280776-17-000075","document":"wf-form4_149755857797011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000075/wf-form4_149755857797011.xml","form_type":"4"}},{"id":4280510,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2017-06-15T20:29:52.000Z","date":"2017-06-14","kind":"purchase","acquired":true,"shares":100,"price":3.075,"value":307.5,"ownership":{"direct":true},"balance_after":9485,"source":{"system":"sec-edgar","filing":"0001280776-17-000075","document":"wf-form4_149755857797011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000075/wf-form4_149755857797011.xml","form_type":"4"}},{"id":4283448,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":108121,"kind":"person","name":"DUNN JOHN MICHAEL","position":1,"cik":"0001238648","reported_name":"DUNN JOHN MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-14T00:08:22.000Z","date":"2017-06-10","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the \"Plan\")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan)."}],"balance_after":45000,"derivative":{"exercise_price":3.2,"expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001280776-17-000064","document":"wf-form4_149739888526652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000128077617000064/wf-form4_149739888526652.xml","form_type":"4"}}]}